PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION

International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent classification[7]:		(11) International publication number: WO 00/33876
A61K 45/06	A1	(43) International publication date: 15 June 2000 (15.06.00)

(21) International application number: PCT/EP99/09380

(22) International filing date: 1 December 1999 (01.12.99)

(30) Data relating to the priority:
198 57 009.8 10 December 1998 (10.12.98) DE

(71) Applicant:
AVENTIS PHARMA DEUTSCHLAND GMBH [DE/DE]; Brüningstrasse 50, D-65929 Frankfurt am Main (DE).

(72) Inventors: LINDNER, Jürgen; Haselhecke 60, D-35041 Marburg (DE). HAASE, Burkhard; Königsteiner Strasse 28, D-65719 Hofheim (DE).


(81) Designated states: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO Patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With the International Search Report.


As printed

(54) Title: FORMULATION WITH AN IMPROVED THERAPEUTIC RANGE, CONTAINING NUCLEOTIDE SYNTHESIS INHIBITORS

(54) Bezeichnung: ZUBEREITUNG MIT VERBESSERTER THERAPEUTISCHER BREITE, ENTHALTEND NUKLEOTIDSYNTHESEINHIBITOREN



(I)



(II)

(57) Abstract

The invention relates to a formulation containing a compound which essentially prevents the enterohepatic circulation of nucleotide synthesis inhibitors or antagonizes the effect of the nucleotide synthesis inhibitors in a delayed manner, and a nucleotide synthesis inhibitor such as brequinar, mycophenolate mofetile, 2-morpholinoethly-(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxoisobenzofuran-5-yl-4-methyl-4-hexenoate, methotrexate, mizoribine and compounds of formula (I) or (II). Said formulation is suitable for treating immunological diseases or cancer or for transplantations.